Septerna Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Septerna Inc (SEPN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Septerna Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 99M vs -M combined for its competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+8.2% annualized vs trailing 12 months).
- Scale: Septerna Inc ranks #87 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Septerna Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
- Structure: Septerna Inc operates in the following segments: G Protein Coupled Receptor.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SEPN Sales vs. its Competitors, Q2 2026
Septerna Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs 22,375.6% for Septerna Inc. Septerna Inc's share of combined industry revenue moved from 0.00% to 0.01%, a gain of 0.01 percentage points.
Septerna Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Septerna Inc | No | Yes | Yes | No |
| High-Confidence Competitors (2) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 50.00 % (4 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SEPN Stock Performance relative to its Competitors
SEPN Stock Performance relative to High-Confidence Competitors
SEPN Stock Performance relative to Similar-Size Competitors
SEPN Stock Performance relative to Similar Growth & Profitability Competitors
Septerna Inc's Comment on Competition and Industry Peers
Septerna Inc's Competitors Named by the Company
Competitive relationships identified from Septerna Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Novo Nordisk A/S | Company report | 85% |
| Bridgebio Pharma Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Septerna Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Septerna Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Septerna Inc | G Protein Coupled Receptor 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).